semaglutide en france Ozempic craze: Approved for diabetes, growing use in obesity semaglutide france Becomes First EU

Clinical studies measuring body composition changes have demonstrated that patients taking FDA-approved anti-obesity medications experience reductions in both subcutaneous abdominal fat (the layer beneath the skin) and visceral adipose tissue (fat surrounding internal organs)

Novo Nordisks commitment to treating obesity is reflected in their extensive research and development for this medication

Excess weight can worsen fibromyalgia symptoms such as pain and fatigue

Originally developed for type 2 diabetes, it was gaining attention as a weight loss medication

Start your weight loss journey today and schedule a complimentary weight loss consultation today